Replies to post #251765 on Biotech Values

[WorstLuck]

Kind of down the middle. Step in the right direction.

[DewDiligence]

Correction—RVNC’s 1Q24 non-GAAP operating expenses were $73.6M, consistent with the low end of the 2024 guidance range of $290-310M.

[jbog]

Dew

1Q24 Daxxify sales were $22.1M, -8% QoQ — due to $2.0M of redeemed coupons and normal seasonality in the aesthetics business — and +44% YoY.

I'm sure there has to be some amount of sales attributed to therapeutics. Would you have any guess?

• 1Q24 dermal-filler sales were 29.6M, -14% QoQ and -2% YoY.

Not being familiar with the landscape of fillers, has someone come out with a superior product" If not there must be something wrong with the injectors relationship.